WO2022042612A1 - Dérivé de dihydropyrrolo[2,3-d]pyridazin-7-one, son procédé de préparation et son utilisation - Google Patents

Dérivé de dihydropyrrolo[2,3-d]pyridazin-7-one, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2022042612A1
WO2022042612A1 PCT/CN2021/114580 CN2021114580W WO2022042612A1 WO 2022042612 A1 WO2022042612 A1 WO 2022042612A1 CN 2021114580 W CN2021114580 W CN 2021114580W WO 2022042612 A1 WO2022042612 A1 WO 2022042612A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
deuterium
substituted
membered
halogen
Prior art date
Application number
PCT/CN2021/114580
Other languages
English (en)
Chinese (zh)
Inventor
邓海兵
辛文群
喻红平
陈椎
徐耀昌
Original Assignee
上海和誉生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海和誉生物医药科技有限公司 filed Critical 上海和誉生物医药科技有限公司
Priority to CN202180047630.2A priority Critical patent/CN116096720A/zh
Publication of WO2022042612A1 publication Critical patent/WO2022042612A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the invention belongs to the field of pharmaceutical synthesis, in particular to a dihydropyrrolo[2,3-d]pyridazin-7-one derivative, a preparation method and application thereof.
  • Fibroblast growth factor receptor is a tyrosine kinase receptor that binds to fibroblast growth factor ligands.
  • FGF fibroblast growth factor
  • FGF When FGF binds to its receptor, the receptor dimerizes and phosphorylates, stimulates the activation of protein kinase activity, and helps activate a series of intracellular signaling pathways, including Ras-MAPK, AKT-PI3K, and phosphorylation Esterase C These signaling pathways are very important for cell growth, proliferation and survival.
  • FGFR inhibitors in clinical trials that have shown clinical responses in patients with abnormal FGFR, and FGFR inhibitors have recently been approved for marketing. However, the rapid emergence of acquired resistance to FGFR inhibitors has been found in clinical trials, resulting in relatively short progression-free survival. Mutations affecting FGFR amino acids may confer resistance to or reduce the activity of FGFR inhibitors.
  • the generation of secondary FGFR kinase domain mutations in response to FGFR inhibitors is an important mechanism for acquiring resistance to FGFR inhibition.
  • Corresponding FGFR point mutations are also present in tumors.
  • Gatekeeper mutations have been reported to be one of the main mechanisms of resistance to tyrosine kinases, and FGFR-resistant mutations have been reported in in vitro cell systems and clinical experiments. Gatekeeper mutations include FGFR3V555M, FGFR2V565F/V565I/V565L, and more. A recent study reported the gatekeeper mutation of FGFR2V565F in three of BGJ398-treated cholangiocarcinoma patients, and two of them had other mutations in other FGFR2 kinase regions.
  • the series of compounds of the present invention have good activity against mutated FGFR, especially against FGFR with gatekeeper mutation, especially against FGFR3 V555M, FGFR2 V565I, FGFR2 V565F, FGFR2 V565L and non-gatekeeper mutation FGFR2 N550K mutation, and are expected to develop new A first-generation FGFR inhibitor.
  • a first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
  • X is C or N;
  • Y is CR 5 , N, NR 6 , O or S;
  • Z is CR 5 or N;
  • Ring A is a 3-12-membered nitrogen-containing heterocyclic group, and the nitrogen atom is connected to a carbonyl group;
  • R 4 is selected from vinyl or ethynyl, and the above groups are independently optionally further substituted by one or more selected from hydrogen, deuterium, halogen, cyano, C 1-10 alkyl, halogen-substituted C 1-10 alkyl, Deuterium substituted C 1-10 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, -C 0-8 alkyl-C(O)OR 9 , -C 0-8 alkyl-C( O) R 10 , -C 0-8 alkyl-C(O)-NR 7a R 7b and -C 0-8 alkyl-NR 7a R 7b are substituted by substituents;
  • R 6 is selected from hydrogen, deuterium, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 5-10 aryl and 5-10 membered Heteroaryl, the above-mentioned groups are optionally further selected from one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 alkyl, deuterium-substituted C 1-10 alkyl, C 3-12 cycloalkyl, 3-12-membered heterocyclyl, C 5-10 -membered aryl, 5-10-membered heterocycle
  • Aryl, O, -C 0-8 alkyl-SF 5 , -C 0-8 alkyl-S(O) r R 8 , -C 0-8 alkyl-OR 9
  • Each R 8 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 5-10 Aryl, 5-10 membered heteroaryl and -NR 11 R 12 , the above-mentioned groups are independently optionally further selected by one or more groups selected from deuterium, halogen, hydroxyl, oxo, C 1-10 alkyl, C 1 -10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 5-10 aryl, C 5- 10 -aryloxy, 5-10-membered heteroaryl, 5-10-membered heteroaryloxy and substituents of -NR 11 R 12 ;
  • Each R 9 is independently selected from hydrogen, deuterium, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 5-10 aryl and 5-10-membered heteroaryl groups, the above-mentioned groups are independently optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, oxo, cyano, C 1-10 alkyl, C 1-10 alkoxy , C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12-membered heterocyclyl, 3-12-membered heterocyclyloxy, C 5-10 aryl, C 5-10 aryloxy, 5-10-membered heteroaryl, 5-10-membered heteroaryloxy and substituents of -NR 11 R 12 ;
  • Each R 10 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 alkyl, C 1-10 alkoxy, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 Cycloalkyl, C 3-12 cycloalkoxy, 3-12-membered heterocyclyl, 3-12-membered heterocyclyloxy, C 5-10 aryl, C 5-10 aryloxy, 5-10-membered heterocycle Aryl, 5-10 membered heteroaryloxy and -NR 11 R 12 , the above-mentioned groups are independently optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, cyano, C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 5-10 aryl, C 5 -10 -aryloxy, 5-10-membered heteroaryl, 5
  • R 11 and R 12 is independently selected from hydrogen, deuterium, hydroxy, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3 -12-membered heterocyclyl, C 5-10 -membered aryl, 5-10-membered heteroaryl, sulfinyl, sulfonyl, methanesulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, amino Sulfonyl, dimethylaminosulfonyl, amino, mono-C 1-10 alkylamino, di-C 1-10 alkylamino and C 1-10 alkanoyl groups, independently optionally further selected by one or more From deuterium, halogen, hydroxyl, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, halogen
  • R 11 and R 12 together with the nitrogen atom to which they are directly attached form a 4-10-membered heterocyclic group or a 5-10-membered heteroaryl group
  • the 4-10-membered heterocyclic group or the 5-10-membered heteroaryl group being either is further selected by one or more selected from deuterium, halogen, hydroxyl, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, halogen substituted C 1-10 alkyl, deuterium substituted C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 5 -10 aryl, C 5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono-C 1-10 alkylamino, di-C 1-10 alkylamino and Substituents of
  • n 0, 1, 2 or 3;
  • n 0, 1, 2, 3, or 4;
  • Each r is independently 0, 1, or 2.
  • R 4 , R 8 , R 9 , R 10 , R 11 , R 12 and r are as defined in the compound of formula (I).
  • the compound of formula (I) is the following compound of formula (IIa) or formula (IIb):
  • Y 1 is NR 6 , O or S
  • Y 2 is CR 5 or N
  • each Z is independently CR 5 or N;
  • Each Ring A is independently a 3-8 membered nitrogen-containing heterocyclic group, and the nitrogen atom is attached to a carbonyl group;
  • Each R 4 is each independently vinyl, and the aforementioned groups are independently optionally further substituted with one or more C 1-4 alkyl groups selected from the group consisting of hydrogen, deuterium, halogen, cyano, C 1-4 alkyl, halogen substituted C 1-4 alkyl , deuterium substituted C 1-4 alkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, -C 0-4 alkyl-C(O)OR 9 , -C 0-4 alkyl-C (O) R 10 , -C 0-4 alkyl-C(O)-NR 7a R 7b and -C 0-4 alkyl-NR 7a R 7b substituents;
  • R 8 , R 9 , R 10 , R 11 , R 12 and r are as defined in the compound of formula (I).
  • each ring A is independently:
  • the compound of formula (I) is the compound of formula (IIIa) or formula (IIIb):
  • Y 1 is O or S
  • R 2a and R 2b is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, C1-4 alkyl, halo-substituted C1-4 alkyl, deuterium substituted C1-4 alkyl, C 3-6 cycloalkyl, -SF 5 , -OR 9 , -C(O)OR 9 , -C(O)R 10 , -OC(O)R 10 and -NR 11 R 12 ;
  • R 9 , R 10 , R 11 and R 12 are as defined in the compound of formula (I).
  • each R 8 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 5-8 aryl, 5-8 membered heteroaryl and -NR 11 R 12 independently optionally further selected by one or more selected from deuterium, halogen, hydroxyl, oxo, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C3-6 cycloalkoxy , 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 aryl, C 5-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -Replaced by the substituent of NR 11 R 12 ;
  • Each R is independently selected from hydrogen, deuterium , C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 5-8 aryl and 5-8-membered heteroaryl, the above-mentioned groups are independently optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, oxo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 aryl, C 5-8 aryloxy, 5 -8-membered heteroaryl, 5-8-membered heteroaryloxy and -NR 11 R 12 substituents;
  • Each R 10 is selected from hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl , C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 aryl, C 5-8 aryloxy, 5-8 membered heteroaryl, 5-8-membered heteroaryloxy and -NR 11 R 12 , the above-mentioned groups are independently optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, cyano, C 1-4 alkyl, C 1-4 Alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 aryl, C 5-8 aryl substituted by the substituents of oxy, 5-8-membered
  • R 11 and R 12 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3 -6-membered heterocyclyl, C 5-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methanesulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, amino Sulfonyl, dimethylaminosulfonyl, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and C 1-4 alkanoyl groups, independently optionally further selected by one or more From deuterium, halogen, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogen substituted C 1-4
  • R 11 and R 12 together with the nitrogen atom to which they are directly attached form a 4-10-membered heterocyclic group or a 5-10-membered heteroaryl group, the 4-10-membered heterocyclic group or the 5-10-membered heteroaryl group being either is further selected from the group consisting of one or more deuterium, halogen, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5 -8 aryl, C 5-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino and Substitu
  • Each R 2a and R 2b is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, Di-deuteromethyl, cyclopropyl, cyclobutyl, oxetanyl, azetidine, -SF5 , methoxy, ethoxy, carboxyl, acetyl, acetoxy, amino, methylamino and dimethylamino.
  • the compounds of formula (I), their stereoisomers or their pharmaceutically acceptable salts include but are not limited to the following compounds:
  • the second aspect of the present invention provides a preparation method of the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt, comprising the following steps:
  • Rings A, X, Y, Z, R 1 , R 2 , R 3 , R 4 , m and n are as defined for compounds of formula (I).
  • a third aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • the present invention also relates to the use of a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of tumor patients resistant to FGFR inhibitors.
  • the tumor patient is a tumor patient with mutations in FGFR V561, V565, N550, N540, V555, E566, K660 and/or V550;
  • the tumor patient is preferred, and the tumor patient is a tumor patient with FGFR2 V565F, V565I, V565L, V565M, N550K, N550H, E566A, E566G, K660M and/or K660Q mutations;
  • the tumor patient is a tumor patient with mutations in FGFR3 V555M/L and/or N540K.
  • the present invention also relates to compounds of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of disease states or disorders mediated by FGFR kinases.
  • the present invention also relates to a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of tumors or cancers mediated by FGFR kinases.
  • the tumor or cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, Gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin lymphoma, or non-Hodgkin lymphoma Lymphoma, Waldenstrom's macroglobulinemia, hair-like lymphoma, cellular lymphoma, Burkitt's lymphoma, glioblastoma, melanoma, or rhabdomyosarcoma.
  • the present invention also relates to the use of a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of myeloproliferative diseases, skeletal or chondrocyte disorders, or hypophosphatemia.
  • the present invention also relates to said myeloproliferative disease selected from polycythemia, essential thrombocythemia or primary myelofibrosis; said bone or chondrocyte disorder selected from dysplasia, chondrodysplasia, dwarfism , Lethal Teratosis (TD), Appel's Syndrome, Crusson's Syndrome, Jackson-Weiss Syndrome, Beare-Stevenson's Syndrome, Pfeiffer's Syndrome or Muscular Dystrophy Syndrome; said The hypophosphatemia is selected from X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, or tumor-induced ovarian softening.
  • the present invention also relates to a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the foregoing, for use with a selective FGFR2 and/or FGFR3 inhibitor for the treatment of and FGFR2 or Use in diseases related to abnormal expression of FGFR3 receptor, abnormal expression and abnormal activity of mutation or corresponding ligand.
  • the present invention also relates to a method of treating a patient with a tumor resistant to an FGFR inhibitor, comprising administering to a patient in need thereof a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
  • the present invention also relates to a method of treating a patient with a tumor having a mutation in FGFR2 V565F, V565I, V565L, V565M, N550K, N550H, E566A, E566G, K660M and/or K660Q, comprising administering to a patient in need thereof a compound of formula (I), its A stereoisomer or a pharmaceutically acceptable salt thereof.
  • the series of compounds of the present invention have good activity against mutated FGFR, especially against FGFR with gatekeeper mutation, especially against FGFR3 V555M, FGFR2 V565I, FGFR2 V565F, FGFR2 V565L and FGFR2 N550K mutations.
  • Alkyl refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon group, preferably a straight-chain alkyl group and a branched-chain alkyl group comprising 1 to 10 or 1 to 6 carbon atoms or 1 to 4 carbon atoms, Including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1, 2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methyl propylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3- Dimethylbutyl,
  • C 1-10 alkyl refers to straight-chain alkyl groups including 1 to 10 carbon atoms and branched alkyl groups
  • C 1-4 alkyl refers to straight-chain alkyl groups including 1 to 4 carbon atoms and A branched-chain alkyl group
  • C 0-8 alkyl refers to a straight-chain alkyl group containing 0 to 8 carbon atoms and a branched alkyl group
  • C 0-4 alkyl refers to a group containing 0 to 4 carbon atoms straight-chain and branched-chain alkyl groups.
  • Cycloalkyl or “carbocycle” refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, and the partially unsaturated cyclic hydrocarbon means that the cyclic hydrocarbon may contain one or more (preferably 1, 2 or 3) double bonds, but none of the rings has a completely conjugated ⁇ electron system, cycloalkyl is divided into monocyclic cycloalkyl, polycyclic cycloalkyl, preferably including 3 to 12 or 3 to 8 or 3 Cycloalkyl groups of up to 6 carbon atoms, for example, "C 3-12 cycloalkyl” refers to cycloalkyl groups including 3 to 12 carbon atoms, “C 3-8 cycloalkyl” refers to cycloalkyl groups including 3 to 8 carbon atoms atomic cycloalkyl, “C 3-6 cycloalkyl” refers to a cycloalkyl group including 3 to 6 carbon atoms, "C 3-4 cyclic
  • Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, Cyclooctyl etc.
  • Polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl groups.
  • “Spirocycloalkyl” refers to polycyclic groups in which a single carbon atom (called a spiro atom) is shared between the monocyclic rings, these may contain one or more (preferably 1, 2 or 3) double bonds, but none of the rings have Fully conjugated pi electron system. According to the number of spiro atoms shared between the rings, spirocycloalkyl groups are classified into single spirocycloalkyl groups, double spirocycloalkyl groups or polyspirocycloalkyl groups, and spirocycloalkyl groups include but are not limited to:
  • fused cycloalkyl refers to an all-carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2 or 3) double bonds, but none of the rings have a fully conjugated pi electron system. According to the number of formed rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl groups, fused cycloalkyl groups include but are not limited to:
  • “Bridged cycloalkyl” refers to an all-carbon polycyclic group in which any two rings share two non-directly attached carbon atoms, these may contain one or more (preferably 1, 2 or 3) double bonds, but none The ring has a fully conjugated pi electron system. According to the number of formed rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, including but not limited to:
  • the cycloalkyl ring can be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl , benzocycloheptyl, etc.
  • Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like.
  • Polycyclic heterocyclyls include spiro, fused and bridged heterocyclyls.
  • Spiroheterocyclyls are classified into mono-, bis-, or poly-spiroheterocyclyls according to the number of spiro atoms shared between the rings.
  • Spiroheterocyclyl groups include, but are not limited to:
  • the heterocyclyl ring can be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:
  • Aryl or “aromatic ring” refers to an all-carbon monocyclic or fused polycyclic (ie, rings sharing adjacent pairs of carbon atoms) groups, polycyclic rings having a conjugated pi electron system (ie, with adjacent ring) groups for carbon atoms, preferably all-carbon aryl groups containing 5-10 or 5-8 carbons, for example, “C 5-10 aryl” refers to all-carbon aryl groups containing 5-10 carbons, “C 5-8 aryl” refers to a full carbon aryl group containing 5-8 carbons, including but not limited to phenyl and naphthyl.
  • the aryl ring can be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, including but not limited to:
  • Heteroaryl refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms including nitrogen, oxygen and S(O)r (where r is the integer 0 , 1, 2) heteroatoms, preferably heteroaromatic systems containing 5-10 or 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl” means containing 5-8 ring atoms Heteroaromatic systems of ring atoms, "5-10 membered heteroaryl” refers to heteroaromatic systems containing 5-10 ring atoms, including but not limited to furyl, thienyl, pyridyl, pyrrolyl, N-alkane pyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl and the like.
  • the heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the
  • Alkenyl means an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched chain alkenyl group containing 2-10 or 2-4 carbons
  • C 2-10 alkenyl refers to a straight-chain or branched alkenyl containing 2-10 carbons
  • C 2-4 alkenyl refers to a straight-chain or branched alkenyl containing 2-4 carbons Branched alkenyl.
  • Alkynyl means an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight-chain or branched-chain alkynyl group containing 2-10 or 2-4 carbons,
  • C 2-10 alkynyl refers to a straight or branched chain alkynyl group containing 2-10 carbons
  • C 2-4 alkynyl refers to a straight or branched chain containing 2-4 carbons alkynyl.
  • ethynyl 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, and the like.
  • Alkoxy refers to -O-alkyl, where alkyl is as defined above, eg, "C 1-10 alkoxy” refers to an alkyloxy group containing 1-10 carbons, C 1-4 alkoxy "Oxy” refers to an alkyloxy group containing 1-4 carbons including, but not limited to, methoxy, ethoxy, propoxy, butoxy, and the like.
  • Cycloalkoxy refers to -O-cycloalkyl, where cycloalkyl is as defined above, for example, “C 3-12 cycloalkoxy” refers to a cycloalkyloxy group containing 3-12 carbons, “C 3-6 cycloalkoxy” refers to a cycloalkyloxy group containing 3-6 carbons, including but not limited to cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • Heterocyclyloxy refers to -O-heterocyclyl, wherein heterocyclyl is as defined above, and heterocyclyloxy, including but not limited to azetidinyloxy, oxetanyloxy, nitrogen Heterocyclopentyloxy, nitrogen, oxhexyloxy, etc.
  • C 1-10 alkanoyl refers to the monovalent atomic group left after C 1-10 alkanoic acid removes the hydroxyl group, usually also expressed as "C 0-9 -C(O)-", for example, "C 1 -C (O)-” means acetyl; “C2 - C(O)-” means propionyl; “C3 - C(O)-” means butyryl or isobutyryl.
  • -C 0-8 alkyl-C(O)R 10 means that the carbonyl group in -C(O)R 10 is attached to a C 0-8 alkyl group, wherein the C 0-8 alkyl group is as defined above.
  • Halo-substituted C 1-10 alkyl refers to 1-10 carbon alkyl groups in which the hydrogen on the alkyl group is optionally substituted by fluorine, chlorine, bromine and iodine atoms, including but not limited to difluoromethyl, dichloro Methyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, etc.
  • Halo-substituted C 1-10 alkoxy refers to a 1-10 carbon alkoxy group in which the hydrogen on the alkyl group is optionally substituted with fluorine, chlorine, bromine, or iodine atoms. Including but not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy and the like.
  • Deuterium-substituted C1-10 alkyl refers to a 1-10 carbon alkyl group in which the hydrogen on the alkyl group is optionally substituted with a deuterium atom. Including but not limited to deuteromethyl, di-deuteromethyl, tri-deuteromethyl and the like.
  • Halogen refers to fluorine, chlorine, bromine or iodine.
  • PE refers to petroleum ether.
  • EtOAc refers to ethyl acetate.
  • DCM dichloromethane.
  • Optional or “optionally” means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, that is, both substituted and unsubstituted .
  • a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may, but need not, be present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group .
  • Substituted means that one or more "hydrogen atoms" in a group are, independently of one another, substituted with the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, in accordance with valence bond theory in chemistry, and those skilled in the art can determine (either experimentally or theoretically) possible or impossible without undue effort replacement. For example, amino or hydroxyl groups with free hydrogen may be unstable when combined with carbon atoms with unsaturated bonds, such as alkenes.
  • Stereoisomer its English name is stereoisomer, refers to the isomers produced by the different arrangements of atoms in the molecule in space. It can be divided into cis-trans isomers and enantiomers. It can also be divided into two categories: enantiomers and diastereomers. Stereoisomers due to rotation of a single bond are called conformational stereo-isomers, and are sometimes called rotamers. Stereoisomers caused by bond length, bond angle, double bond in the molecule, ring, etc. are called configuration stereo-isomers, and configuration isomers are divided into two categories.
  • the isomers caused by the double bond or the single bond of the ring carbon atom not being able to rotate freely are called geometric isomers, also known as cis-trans isomers, which are divided into Z, E two configurations.
  • geometric isomers also known as cis-trans isomers, which are divided into Z, E two configurations.
  • cis-2-butene and trans-2-butene are a pair of geometric isomers, and the stereoisomers with different optical properties caused by the absence of anti-axial symmetry in the molecule are called optical isomers ( optical isomer), divided into R and S configurations.
  • the "stereoisomer" may be understood to include one or more of the above-mentioned enantiomers, configurational isomers and conformational isomers unless otherwise specified.
  • “Pharmaceutically acceptable salts” in the present invention refer to pharmaceutically acceptable acid addition salts or base addition salts, including inorganic and organic acid salts, which can be prepared by methods known in the art.
  • “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as a physiological/pharmaceutically acceptable carrier and excipients.
  • the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
  • the structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts ([delta]) are given in parts per million (ppm). NMR was measured by Bruker AVANCE-400 nuclear magnetic instrument, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3 ), and the internal standard was four Methylsilane (TMS).
  • DMSO-d 6 dimethyl sulfoxide
  • CD 3 OD deuterated methanol
  • CDCl 3 deuterated chloroform
  • TMS Methylsilane
  • the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the specifications used for TLC are 0.15mm ⁇ 0.20mm, and the specifications used for TLC separation and purification products are 0.4mm ⁇ 0.5mm.
  • Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
  • the starting materials in the examples of the present invention are known and commercially available, or can be synthesized using or according to methods known in the art.
  • the first step Synthesis of 2-cyclopropyl-6,8-difluoro-7-iodoimidazo[1,2-a]pyridine
  • the second step Synthesis of 2-cyclopropyl-7-ethynyl-6,8-difluoroimidazo[1,2-a]pyridine
  • the first step Synthesis of 2-cyclopropyl-6-fluoro-7-iodoimidazo[1,2-a]pyridine
  • the second step Synthesis of 2-cyclopropyl-7-ethynyl-6-fluoroimidazo[1,2-a]pyridine
  • the first step the synthesis of N-(5-bromo-2-hydroxyphenyl) cyclopropanecarboxamide
  • the second step the synthesis of 5-bromo-2-cyclopropylbenzo[d]oxazole
  • N-(5-Bromo-2-hydroxyphenyl)cyclopropanecarboxamide (1.04 g, 4.06 mmol) was dissolved in acetonitrile (30 mL), and triphenylphosphine (4.26 g, 16.2 mmol) was added successively at room temperature.
  • Carbon chloride (1.25 g, 8.1 mmol).
  • the mixture was stirred at 60°C for 1 hour, diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated and separated by column chromatography to obtain 5-bromo-2-cyclopropylbenzoic acid.
  • Oxazole (548 mg, yield: 55%).
  • the third step Synthesis of 2-cyclopropyl-5-((trimethylsilyl)ethynyl)benzo[d]oxazole
  • the fourth step the synthesis of 2-cyclopropyl-5-ethynylbenzo[d]oxazole
  • the first step the synthesis of N-(5-bromo-2,4-difluorophenyl) cyclopropanecarboxamide
  • the second step the synthesis of N-(5-bromo-2,4-difluorophenyl) cyclopropylmethylthioamide
  • N-(5-Bromo-2,4-difluorophenyl)cyclopropanecarboxamide 1.0 g, 3.6 mmol
  • Lawson's reagent 750 mg, 1.85 mmol
  • acetonitrile 25 mL
  • the third step Synthesis of 5-bromo-2-cyclopropyl-6-fluorobenzo[d]thiazole
  • the fourth step the synthesis of 2-cyclopropyl-5-ethynyl-6-fluorobenzo[d]thiazole
  • the first step the synthesis of N-(2,4-difluorophenyl) cyclopropanecarboxamide
  • the third step synthesis of 2-cyclopropyl-4,6-difluorobenzo[d]thiazole
  • N-(2,4-difluorophenyl)cyclopropylmethylthioamide (1 g, 4.69 mmol) was dissolved in sodium hydroxide solution (1.69 g, 42.21 mmol, 5 mL of ethanol and 10 mL of water), and the resulting solution was added dropwise to Preheated to a K 3 Fe(CN) 6 aqueous solution (6.18 g, 18.78 mmol, 10 mL of water) at 90° C. After stirring for 2 hours, the heating was stopped immediately. After cooling, it was adjusted to weakly acidic with concentrated hydrochloric acid, and extracted with ethyl acetate.
  • the fourth step the synthesis of 2-cyclopropyl-4,6-difluorobenzo[d]thiazole-5-carbaldehyde
  • the fifth step the synthesis of 2-cyclopropyl-5-ethynyl-4,6-difluorobenzo[d]thiazole
  • Intermediate 12 is prepared by selecting corresponding raw materials with reference to all or part of the synthesis methods of intermediate 11:
  • the first step the synthesis of 2-amino-4-bromo-5-fluorophenol
  • the second step the synthesis of 5-bromo-6-fluorobenzo[d]oxazole-2(3H)-thione
  • the third step Synthesis of 5-bromo-2-chloro-6-fluorobenzo[d]oxazole
  • the fourth step the synthesis of 5-bromo-6-fluoro-N-methylbenzo[d]oxazol-2-amine
  • the fifth step the synthesis of 6-fluoro-N-methyl-5-((trimethylsilyl)ethynyl)benzo[d]oxazol-2-amine
  • the first step synthesis of 2-amino-3,5-difluorophenol
  • the third step synthesis of 2-chloro-4,6-difluorobenzo[d]oxazole
  • the fourth step the synthesis of 2-(azetidin-1-yl)-4,6-difluorobenzo[d]oxazole
  • the fifth step the synthesis of 2-(azetidine-1-yl)-4,6-difluorobenzo[d]oxazole-5-carbaldehyde
  • the sixth step the synthesis of 2-(azetidin-1-yl)-5-ethynyl-4,6-difluorobenzo[d]oxazole
  • the first step Synthesis of diethyl(2E,4E,6E)-3,6-dicyano-2,7-dihydroxyoctane-2,4,6-trienedioate
  • the second step the synthesis of ethyl 3-cyano-1H-pyrrole-2-carboxylate
  • the third step synthesis of ethyl (S)-1-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-3-cyano-1H-pyrrole-2-carboxylate
  • the fourth step ethyl (S)-1-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-3-cyano-4-iodo-1H-pyrrole-2-carboxylate synthesis
  • Step 7 (S)-1-(1-Acryloylpyrrolidin-3-yl)-4-amino-3-iodo-1,6-dihydro-7H-pyrrolo[2,3-d]pyridine Synthesis of oxazin-7-ones
  • Embodiment 2 ⁇ 18 selects corresponding raw material to prepare with reference to all or part of the synthetic method of embodiment 1:
  • the compounds of the examples of the present invention are used to stably express the TEL-FGFR2WT intracellular kinase domain fusion protein by transfection in Baf cells, or the intracellular domain fusion protein containing FGFR2 V564I, V564F, V564L, N549K, K659M mutations
  • the cell lines were used to measure the proliferation effect of Baf3-Tel-FGFR2WT and various mutant FGFR2 cells.
  • the specific test process is as follows:
  • CCG CellTiter Glo
  • the compounds of the examples of the present invention were used to stably express TEL-FGFR3WT intracellular kinase domain fusion protein by transfection in Baf cells, or a cell line containing FGFR3V555M or FGFR3N540K mutant intracellular domain fusion protein to measure cell proliferation Effect.
  • the specific test process is as follows:
  • CCG CellTiter Glo
  • the series of compounds of the present invention have strong inhibitory effects on both the wild-type FGFR and the mutant FGFR at the cellular level, and the inhibitory effect in the mutation is not weakened.

Abstract

L'invention concerne un dérivé de dihydropyrrolo[2,3-d]pyridazin-7-one ayant la structure de formule (I), son procédé de préparation, une composition pharmaceutique le contenant, ainsi que son utilisation en tant qu'inhibiteur de FGFR et de mutation, et une utilisation de celui-ci dans la préparation d'un médicament pour le traitement et/ou la prévention d'une tumeur ou d'un cancer au moins partiellement médié par une FGFR kinase et une tumeur chez un patient ayant une résistance à un inhibiteur de FGFR, et en particulier dans la préparation d'un médicament pour le traitement et/ou la prévention d'une tumeur chez un patient ayant une mutation dans V561, V565, N550, N540, V555, E566, K660 et/ou V550 sur une voie de signalisation de FGFR. Les substituants dans la formule (I) ont les mêmes définitions que celles données dans la description.
PCT/CN2021/114580 2020-08-27 2021-08-25 Dérivé de dihydropyrrolo[2,3-d]pyridazin-7-one, son procédé de préparation et son utilisation WO2022042612A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180047630.2A CN116096720A (zh) 2020-08-27 2021-08-25 二氢吡咯并[2,3-d]哒嗪-7-酮衍生物，其制备方法和应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010878356 2020-08-27
CN202010878356.0 2020-08-27

Publications (1)

Publication Number Publication Date
WO2022042612A1 true WO2022042612A1 (fr) 2022-03-03

Family

ID=80354669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/114580 WO2022042612A1 (fr) 2020-08-27 2021-08-25 Dérivé de dihydropyrrolo[2,3-d]pyridazin-7-one, son procédé de préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN116096720A (fr)
WO (1) WO2022042612A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003710A (zh) * 2023-07-19 2023-11-07 镇江先锋植保科技有限公司 一种2-巯基-6-氯苯并恶唑的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015178955A1 (fr) * 2014-05-19 2015-11-26 Eternity Bioscience Inc. Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase
CN106573001A (zh) * 2014-07-07 2017-04-19 永恒生物科技公司 作为蛋白激酶抑制剂的氨基哒嗪酮化合物
CN109476666A (zh) * 2016-06-22 2019-03-15 上海复尚慧创医药研究有限公司 作为激酶抑制剂的取代的吡咯并[2,3-d]哒嗪-4-酮和吡唑并[3,4-d]哒嗪-4-酮

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015178955A1 (fr) * 2014-05-19 2015-11-26 Eternity Bioscience Inc. Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase
CN106573001A (zh) * 2014-07-07 2017-04-19 永恒生物科技公司 作为蛋白激酶抑制剂的氨基哒嗪酮化合物
CN109476666A (zh) * 2016-06-22 2019-03-15 上海复尚慧创医药研究有限公司 作为激酶抑制剂的取代的吡咯并[2,3-d]哒嗪-4-酮和吡唑并[3,4-d]哒嗪-4-酮

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003710A (zh) * 2023-07-19 2023-11-07 镇江先锋植保科技有限公司 一种2-巯基-6-氯苯并恶唑的制备方法

Also Published As

Publication number Publication date
CN116096720A (zh) 2023-05-09

Similar Documents

Publication Publication Date Title
WO2020073949A1 (fr) Régulateur de dérivés hétéroaromatiques contenant de l'azote, procédé de préparation associé et utilisation correspondante
TWI602816B (zh) 新穎化合物
KR101914720B1 (ko) 암 질환의 치료를 위한 fgfr 키나제 억제제로서의 치환된 벤조피라진 유도체
KR102072869B1 (ko) Fgfr 키나제 조절제로서의 퀴놀린
JP5538522B2 (ja) アザアズレン化合物
WO2020073945A1 (fr) Inhibiteur de dérivé bicyclique, son procédé de préparation et son utilisation
CN112552294B (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
BR112015026830B1 (pt) Composto, composição farmacêutica, combinação, produto, e, uso de um composto
KR20150016595A (ko) Fgfr 억제제로서의 프테리딘
HUE029275T2 (en) Phthalazinone ketone derivative, method of preparation and therapeutic use
BR112014010179B1 (pt) composto, composição farmacêutica, e, uso de um composto
TW201609699A (zh) 具有ａｌｋ抑制活性的化合物及其製備與用途
JP2010538094A (ja) チロシンキナーゼ阻害剤としてのピラゾロピリジン類
WO2018010514A1 (fr) Composé hétérocyclique utilisé en tant qu'inhibiteur de fgfr
WO2023098425A1 (fr) Inhibiteurs de kras, leur procédé de préparation et leur utilisation pharmaceutique
WO2019223766A1 (fr) Inhibiteur de fgfr, son procédé de préparation et son utilisation pharmaceutique
WO2022042612A1 (fr) Dérivé de dihydropyrrolo[2,3-d]pyridazin-7-one, son procédé de préparation et son utilisation
WO2020221209A1 (fr) Inhibiteur de cd73, son procédé de préparation et son utilisation
WO2022033532A1 (fr) Fgfr et inhibiteur de mutation de celui-ci, procédé de préparation correspondant et utilisation associée
WO2022033416A1 (fr) Composé cyclique condensé utilisé en tant qu'inhibiteur d'egfr, son procédé de préparation et son utilisation
WO2022033455A1 (fr) Dérivé de triazine ayant une activité inhibitrice d'egfr, son procédé de préparation et son utilisation
WO2022042613A1 (fr) Dérivé de 1h-pyrazol-4-amide, son procédé de préparation et son utilisation
WO2020052349A1 (fr) Inhibiteur de fgfr, son procédé de préparation et son application
WO2019242587A1 (fr) Inhibiteur hautement sélectif de fgfr i, son procédé de préparation et son utilisation
CN115701429B (zh) 4-(1h-吲哚-1-基)嘧啶-2-氨基衍生物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21860447

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21860447

Country of ref document: EP

Kind code of ref document: A1